Clinical Trial Update: Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bicalutamide in combination with aromatase inhibitors for ER-positive, AR-positive, HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: Xu fei | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN